{"id":69511,"date":"2025-07-01T00:01:42","date_gmt":"2025-07-01T00:01:42","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/07\/01\/avicanna-announces-results-of-annual-general-meeting\/"},"modified":"2025-07-01T00:01:42","modified_gmt":"2025-07-01T00:01:42","slug":"avicanna-announces-results-of-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/avicanna-announces-results-of-annual-general-meeting\/","title":{"rendered":"Avicanna Announces Results of Annual General Meeting"},"content":{"rendered":"
\n

TORONTO, June 30, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (\u201cAvicanna<\/strong>\u201d or the \u201cCompany<\/strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that all of management\u2019s nominees listed in the Company\u2019s Management Information Circular dated May 27, 2025 (\u201cCircular\u201d) were elected as directors of the Company at the Company\u2019s Annual General Meeting of Shareholders held on June 30, 2025 (\u201cMeeting\u201d).<\/p>\n

The detailed results of the vote for the election of directors held at the Meeting are as follows:<\/p>\n\n\n\n\n\n\n\n
Name of<\/strong>
NOMINEE<\/strong><\/td>\n		# Votes Cast<\/strong>
FOR<\/strong><\/td>\n		% Votes Cast<\/strong>
FOR<\/strong><\/td>\n		# Votes<\/strong>
WITHHELD\/ABSTAIN<\/strong><\/td>\n		% Votes<\/strong>
WITHHELD\/ABSTAIN<\/strong><\/td>\n<\/tr>\n
Aras Azadian<\/td>\n40,471,719<\/td>\n99.985%<\/td>\n6,047<\/td>\n0.015%<\/td>\n<\/tr>\n
Giancarlo Davila Char<\/td>\n40,469,499<\/td>\n99.980%<\/td>\n8,267<\/td>\n0.020%<\/td>\n<\/tr>\n
Paul Fornazzari<\/td>\n40,469,324<\/td>\n99.979%<\/td>\n8,442<\/td>\n0.021%<\/td>\n<\/tr>\n
Eileen McCormack<\/td>\n40,471,900<\/td>\n99.986%<\/td>\n5,866<\/td>\n0.014%<\/td>\n<\/tr>\n
John McVicar<\/td>\n40,469,499<\/td>\n99.980%<\/td>\n8,267<\/td>\n0.020%<\/td>\n<\/tr>\n<\/table>\n

The Company\u2019s shareholders also approved the reappointment of Ramirez Jimenez International CPAs as the Company\u2019s auditors for the ensuing year and authorized the board of directors to fix the auditors\u2019 remuneration at the Meeting.<\/p>\n

About Avicanna:<\/strong><\/p>\n

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.<\/p>\n